Evidence map›Paper›PMID 29107268›Full record

ReviewThe Urologic clinics of North America2017

Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators.

Stacy Loeb, Hasan Dani

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Urologic clinics of North America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Stacy LoebDepartment of Urology, New York University, New York, NY, USA; Department of Population Health, New York University, New York, NY, USA; Department of Urology, Manhattan Veterans Affairs Medical Center, New York, NY, USA. Electronic address: stacyloeb@gmail.com.
Hasan DaniDepartment of Urology, SUNY Downstate College of Medicine, Brooklyn, NY, USA.

Funding

Optimal Strategy for Conservative Management of Prostate CancerK07CA178258 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LOEB, STACY · 2013 to 2017
$889k
NCI NIH HHS K07 CA178258
6 · The paper itself

Abstract

This article describes markers used for prostate biopsy decisions, including prostrate-specific antigen (PSA), free PSA, the prostate health index, 4Kscore, PCA3, and ConfirmMDx. It also summarizes the use of nomograms combining multiple variables for prostate cancer detection.

Indexed as

Biomarkers, TumorBiopsyHumansMaleNomogramsProstate-Specific AntigenProstatic NeoplasmsRisk AssessmentBiomarkers, TumorProstate-Specific AntigenBiomarkersNomogramsProstate biopsyProstate cancerProstate-specific antigen

Identifiers

PMID29107268
PMCPMC6004126

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.